These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 8120920)
1. Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma. Taetle R; Dos Santos B; Ohsugi Y; Koishihara Y; Yamada Y; Messner H; Dalton W J Natl Cancer Inst; 1994 Mar; 86(6):450-5. PubMed ID: 8120920 [TBL] [Abstract][Full Text] [Related]
2. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells. Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167 [TBL] [Abstract][Full Text] [Related]
3. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. White S; Taetle R; Seligman PA; Rutherford M; Trowbridge IS Cancer Res; 1990 Oct; 50(19):6295-301. PubMed ID: 2400993 [TBL] [Abstract][Full Text] [Related]
4. Differential sensitivity of human myeloma cell lines and normal bone marrow colony forming cells to a recombinant diphtheria toxin-interleukin 6 fusion protein. Chadwick DE; Jean LF; Jamal N; Messner HA; Murphy JR; Minden MD Br J Haematol; 1993 Sep; 85(1):25-36. PubMed ID: 8251407 [TBL] [Abstract][Full Text] [Related]
5. Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro. Goto H; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Ashihara E; Oku N; Inaba T; Fujita N; Koishihara Y Jpn J Cancer Res; 1994 Sep; 85(9):958-65. PubMed ID: 7961126 [TBL] [Abstract][Full Text] [Related]
6. Effects of monoclonal anti-transferrin receptor antibodies on in vitro growth of human solid tumor cells. Taetle R; Honeysett JM Cancer Res; 1987 Apr; 47(8):2040-4. PubMed ID: 3828993 [TBL] [Abstract][Full Text] [Related]
7. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Shima Y; Nishimoto N; Ogata A; Fujii Y; Yoshizaki K; Kishimoto T Blood; 1995 Feb; 85(3):757-64. PubMed ID: 7530506 [TBL] [Abstract][Full Text] [Related]
8. A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells. Huang YW; Vitetta ES Hybridoma; 1993 Oct; 12(5):621-30. PubMed ID: 8300137 [TBL] [Abstract][Full Text] [Related]
9. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Hitzler JK; Martinez-Valdez H; Bergsagel DB; Minden MD; Messner HA Blood; 1991 Oct; 78(8):1996-2004. PubMed ID: 1912582 [TBL] [Abstract][Full Text] [Related]
10. Expression and production of interleukin 10 in human myeloma cell lines. Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145 [TBL] [Abstract][Full Text] [Related]
11. C-kit ligand (SCF) in human multiple myeloma cells. Lemoli RM; Fortuna A Leuk Lymphoma; 1996 Feb; 20(5-6):457-64. PubMed ID: 8833403 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Lu ZY; Zhang XG; Rodriguez C; Wijdenes J; Gu ZJ; Morel-Fournier B; Harousseau JL; Bataille R; Rossi JF; Klein B Blood; 1995 May; 85(9):2521-7. PubMed ID: 7727780 [TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266. Anthes JC; Zhan Z; Gilchrest H; Egan RW; Siegel MI; Billah MM Biochem J; 1995 Jul; 309 ( Pt 1)(Pt 1):175-80. PubMed ID: 7619053 [TBL] [Abstract][Full Text] [Related]
14. A ciliary neurotrophic factor-sensitive human myeloma cell line. Gu ZJ; Zhang XG; Hallet MM; Lu ZY; Wijdenes J; Rossi JF; Klein B Exp Hematol; 1996 Aug; 24(10):1195-200. PubMed ID: 8765494 [TBL] [Abstract][Full Text] [Related]
15. Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. Keller ET; Ershler WB J Immunol; 1995 Apr; 154(8):4091-8. PubMed ID: 7706747 [TBL] [Abstract][Full Text] [Related]
16. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells. de Hon FD; Ehlers M; Rose-John S; Ebeling SB; Bos HK; Aarden LA; Brakenhoff JP J Exp Med; 1994 Dec; 180(6):2395-400. PubMed ID: 7964514 [TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2). Van Riet I; De Greef C; Aharchi F; Woischwill C; De Waele M; Bakkus M; Lacor P; Schots R; Van Camp B Leukemia; 1997 Feb; 11(2):284-93. PubMed ID: 9009094 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241 [TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Westendorf JJ; Ahmann GJ; Greipp PR; Witzig TE; Lust JA; Jelinek DF Leukemia; 1996 May; 10(5):866-76. PubMed ID: 8656685 [TBL] [Abstract][Full Text] [Related]
20. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Uchiyama H; Barut BA; Mohrbacher AF; Chauhan D; Anderson KC Blood; 1993 Dec; 82(12):3712-20. PubMed ID: 8260708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]